136 related articles for article (PubMed ID: 38556267)
1. Risk Assessment in Pulmonary Arterial Hypertension.
Akagi S
Circ J; 2024 Mar; ():. PubMed ID: 38556267
[No Abstract] [Full Text] [Related]
2. Current clinical utilization of risk assessment tools in pulmonary arterial hypertension: a descriptive survey of facilitation strategies, patterns, and barriers to use in the United States.
Wilson M; Keeley J; Kingman M; Wang J; Rogers F
Pulm Circ; 2020; 10(3):2045894020950186. PubMed ID: 33062258
[TBL] [Abstract][Full Text] [Related]
3. Risk Assessment Tool Implementation in Congenital Heart Disease-Associated Pulmonary Arterial Hypertension.
Yaylalı YT; Yağmur B; Sinan ÜY; Meriç M; Başarıcı İ; Kılıçkıran Avcı B; Şenol H; Nalbantgil S; Küçükoğlu S; Öngen Z
Anatol J Cardiol; 2023 Aug; 27(8):479-485. PubMed ID: 37288853
[TBL] [Abstract][Full Text] [Related]
4. Real-world experience using combination therapy with riociguat and risk assessment using REVEAL Lite 2.0 in patients with pulmonary arterial hypertension.
Sahay S; Rahaghi F
Pulm Circ; 2020; 10(1):2045894020910098. PubMed ID: 32166019
[TBL] [Abstract][Full Text] [Related]
5. Plasma adrenomedullin peptides and precursor levels in pulmonary arterial hypertension disease severity and risk stratification.
Bouzina H; Rådegran G
Pulm Circ; 2020; 10(3):2045894020931317. PubMed ID: 32595932
[TBL] [Abstract][Full Text] [Related]
6. Enrichment Benefits of Risk Algorithms for Pulmonary Arterial Hypertension Clinical Trials.
Scott JV; Garnett CE; Kanwar MK; Stockbridge NL; Benza RL
Am J Respir Crit Care Med; 2021 Mar; 203(6):726-736. PubMed ID: 32937078
[No Abstract] [Full Text] [Related]
7. Plasma proteome analysis in patients with pulmonary arterial hypertension: an observational cohort study.
Rhodes CJ; Wharton J; Ghataorhe P; Watson G; Girerd B; Howard LS; Gibbs JSR; Condliffe R; Elliot CA; Kiely DG; Simonneau G; Montani D; Sitbon O; Gall H; Schermuly RT; Ghofrani HA; Lawrie A; Humbert M; Wilkins MR
Lancet Respir Med; 2017 Sep; 5(9):717-726. PubMed ID: 28624389
[TBL] [Abstract][Full Text] [Related]
8. Serological biomarkers as risk factors of SLE-associated pulmonary arterial hypertension: a systematic review and meta-analysis.
Wang J; Qian J; Wang Y; Zhao J; Wang Q; Tian Z; Li M; Zeng X
Lupus; 2017 Nov; 26(13):1390-1400. PubMed ID: 28409522
[TBL] [Abstract][Full Text] [Related]
9. [Applying of magnetic resonance tomography for assessment of cardiac remodeling and risk stratification in patients with pulmonary arterial hypertension].
Shariya AM; Martynyuk TV; Shariya MA; Ustyuzhanin DV
Ter Arkh; 2023 May; 95(4):291-295. PubMed ID: 38158975
[TBL] [Abstract][Full Text] [Related]
10. Genetic determinants of risk in pulmonary arterial hypertension: international genome-wide association studies and meta-analysis.
Rhodes CJ; Batai K; Bleda M; Haimel M; Southgate L; Germain M; Pauciulo MW; Hadinnapola C; Aman J; Girerd B; Arora A; Knight J; Hanscombe KB; Karnes JH; Kaakinen M; Gall H; Ulrich A; Harbaum L; Cebola I; Ferrer J; Lutz K; Swietlik EM; Ahmad F; Amouyel P; Archer SL; Argula R; Austin ED; Badesch D; Bakshi S; Barnett C; Benza R; Bhatt N; Bogaard HJ; Burger CD; Chakinala M; Church C; Coghlan JG; Condliffe R; Corris PA; Danesino C; Debette S; Elliott CG; Elwing J; Eyries M; Fortin T; Franke A; Frantz RP; Frost A; Garcia JGN; Ghio S; Ghofrani HA; Gibbs JSR; Harley J; He H; Hill NS; Hirsch R; Houweling AC; Howard LS; Ivy D; Kiely DG; Klinger J; Kovacs G; Lahm T; Laudes M; Machado RD; MacKenzie Ross RV; Marsolo K; Martin LJ; Moledina S; Montani D; Nathan SD; Newnham M; Olschewski A; Olschewski H; Oudiz RJ; Ouwehand WH; Peacock AJ; Pepke-Zaba J; Rehman Z; Robbins I; Roden DM; Rosenzweig EB; Saydain G; Scelsi L; Schilz R; Seeger W; Shaffer CM; Simms RW; Simon M; Sitbon O; Suntharalingam J; Tang H; Tchourbanov AY; Thenappan T; Torres F; Toshner MR; Treacy CM; Vonk Noordegraaf A; Waisfisz Q; Walsworth AK; Walter RE; Wharton J; White RJ; Wilt J; Wort SJ; Yung D; Lawrie A; Humbert M; Soubrier F; Trégouët DA; Prokopenko I; Kittles R; Gräf S; Nichols WC; Trembath RC; Desai AA; Morrell NW; Wilkins MR; ; ;
Lancet Respir Med; 2019 Mar; 7(3):227-238. PubMed ID: 30527956
[TBL] [Abstract][Full Text] [Related]
11. Selexipag treatment in patients with systemic sclerosis-associated pulmonary arterial hypertension in clinical practice, a case series.
Lemmers JM; Fretheim H; Knaapen HK; van den Hoogen FH; van Haren-Willems JH; Duijnhouwer AL; van Dijk AP; van den Ende CH; Hoffmann-Vold AM; Vonk MC
J Scleroderma Relat Disord; 2020 Oct; 5(3):NP7-NP11. PubMed ID: 35382522
[TBL] [Abstract][Full Text] [Related]
12. The Evolution of Risk Assessment in Pulmonary Arterial Hypertension.
Murthy S; Benza R
Methodist Debakey Cardiovasc J; 2021; 17(2):134-144. PubMed ID: 34326933
[TBL] [Abstract][Full Text] [Related]
13. Tolerability and clinical efficacy of inhaled treprostinil in patients with group 1 pulmonary arterial hypertension.
Enderby CY; Burger C
Ther Adv Chronic Dis; 2018 Sep; 9(9):171-177. PubMed ID: 30181846
[TBL] [Abstract][Full Text] [Related]
14. Higher plasma fibroblast growth factor 23 levels are associated with a higher risk profile in pulmonary arterial hypertension.
Bouzina H; Hesselstrand R; Rådegran G
Pulm Circ; 2019; 9(4):2045894019895446. PubMed ID: 31908768
[TBL] [Abstract][Full Text] [Related]
15. Peripartum outcomes in a large population of women with pulmonary arterial hypertension associated with congenital heart disease.
Li Q; Dimopoulos K; Liu T; Xu Z; Liu Q; Li Y; Zhang J; Gu H
Eur J Prev Cardiol; 2019 Jul; 26(10):1067-1076. PubMed ID: 30971116
[TBL] [Abstract][Full Text] [Related]
16. Analysis of relationship between P wave dispersion and diagnosis of pulmonary arterial hypertension and risk stratification.
Luo J; Sun J; Xu L; Chen J; Chen Y; Chen W; Qiu H; Luo X; Chen S; Li J
J Electrocardiol; 2023; 81():94-100. PubMed ID: 37657302
[TBL] [Abstract][Full Text] [Related]
17. Improvements in French risk stratification score were correlated with reductions in mean pulmonary artery pressure in pulmonary arterial hypertension: a subanalysis of the Japan Pulmonary Hypertension Registry (JAPHR).
Tamura Y; Kumamaru H; Abe K; Satoh T; Miyata H; Ogawa A; Tanabe N; Hatano M; Yao A; Tsujino I; Fukuda K; Kimura H; Kuwana M; Matsubara H; Tatsumi K;
BMC Pulm Med; 2021 Jan; 21(1):28. PubMed ID: 33446139
[TBL] [Abstract][Full Text] [Related]
18. The role of serial right heart catheterization in risk stratification and management of pulmonary arterial hypertension.
Sharma D; Shah RJ; Sreenivasan J; Kafle P; Gupta R; Levine A; Lanier GM; Aronow WS
Expert Rev Cardiovasc Ther; 2022 Jul; 20(7):543-547. PubMed ID: 35726644
[TBL] [Abstract][Full Text] [Related]
19. Pulmonary arterial hypertension in children.
Widlitz A; Barst RJ
Eur Respir J; 2003 Jan; 21(1):155-76. PubMed ID: 12570125
[TBL] [Abstract][Full Text] [Related]
20. Interest of TAPSE/sPAP ratio for noninvasive pulmonary arterial hypertension risk assessment.
Fauvel C; Raitiere O; Boucly A; De Groote P; Renard S; Bertona J; Lamblin N; Artaud-Macari E; Viacroze C; Schleifer D; Dominique S; Pichon J; Jais X; Montani D; Sitbon O; Savale L; Humbert M; Bauer F
J Heart Lung Transplant; 2022 Dec; 41(12):1761-1772. PubMed ID: 36202691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
